Nuritas Announces Formation of Scientific Advisory Board
DUBLIN, Ireland, Oct. 09, 2018 (GLOBE NEWSWIRE) -- Nuritas, a biotechnology company discovering life-changing drugs through the power of artificial intelligence (AI) based peptide discovery, today announced the formation of its scientific advisory board (SAB) with four key appointments: Justin Siegel, Ph.D., David Chernoff, M.D., J Bruce German, Ph.D. and Luke O’Neill, Ph.D.
“We are delighted to have attracted some of the world’s leading experts in drug discovery, metabolism, immunology, food for health, proteomics and molecular diagnostics to support Nuritas as we advance our AI platform and bioactive peptide discovery to address the world’s growing healthcare needs,” said Emmet Browne, chief executive officer of Nuritas. “The formation of our SAB serves to further strengthen Nuritas’s unique approach to discover peptide-based therapies with unmatched speed and accuracy.”
Dr. Nora Khaldi, Ph.D., founder and chief scientific officer of Nuritas said, “The scientific guidance of this group of experts will be key as we accelerate and develop our unique peptide discoveries to improve human health. We are continuing to expand our scientific teams at Nuritas and the addition of the SAB further strengthens this.”
Justin Siegel, Ph.D., is an associate professor of chemistry, biochemistry and molecular medicine in the Genome Center at University of California, Davis. Dr. Siegel combines computational and experimental tools to design and discover enzymes for a wide range of applications including the treatment of human disease, the production of fuels and chemicals and the application of discovered enzymes within food systems to promote health and sustainability. As the faculty director of the Innovation Institute for Food and Health (IIFH), he has accelerated the institute’s innovation cycle and deployment of products and processes that enable safe, sustainable and secure nutrition for all. Dr. Siegel received his Ph.D. in biomolecular structure and design from the University of Washington and has a wealth of experience in translational research, having founded four companies, and currently serves as the director of business development for the Rosetta Commons.
David Chernoff, M.D., is the chief medical officer of SetPoint Medical, a clinical-stage biomedical technology company developing bioelectronic therapy for chronic inflammatory disease. He has 25 years of molecular diagnostics and biopharmaceutical experience and has served as a translational medicine consultant for more than 40 biotechnology, pharmaceutical and medical device companies, and as chief medical officer for a number of companies including Crescendo Bioscience, Adamas Pharma, Tethys Biosciences and Aquinox Pharma. He served as vice president of corporate technology at Elan Pharmaceuticals and medical director at Chiron Diagnostics where he played a pivotal role in the development of viral load assays for HIV, HCV, HBV and CMV. He was a principal with life sciences management consulting firm Keelin Reeds Ventures and entrepreneur in residence and operating partner at TPG Biotech VC Fund. Dr. Chernoff received his M.D. from New York University and completed his medical training and research in internal medicine, rheumatology and infectious disease at UCSF Medical Center.
J Bruce German, Ph.D., is food science and technology director at the Foods for Health Institute at the University of California, Davis and the co-founder of Evolve Biosystems. With the goal of improving human health through diet, Dr. German is studying the structure and function of dietary lipids, the evolution of lactation and the role of milk components in food and health. Dr. German is conducting research studies on the use of metabolic assessments to personalize diet and health, and to better understand the molecular basis for differences in human metabolism and the response to chemical composition and structural organization of foods. He received his Ph.D. from Cornell University and has published more than 400 papers on milk, lipids and food, metabolism and metabolite measurements and food functions and holds numerous patents for technologies and applications of bioactive agents.
Luke O’Neill, Ph.D., is the chair of biochemistry at Trinity College Dublin where he leads the Inflammation Research Group. Dr. O’Neill studies the molecular basis of inflammation with a focus on innate immunity, toll-like receptors, inflammasomes and metabolic reprogramming in macrophage activation and has co-founded three companies, each developing new treatments for inflammatory diseases. Dr. O’Neill was recognized by Clarivates/Thompson Reuters as one of the world’s most influential scientists, being in the top 1% in the field of immunology and has won numerous awards for his research including the European Federation of Immunology Societies medal, the International Cytokine and Interferon Society Milstein Award, The Royal Dublin Society Boyle Medal for Scientific Excellence and The Royal Irish Academy Gold Medal for Life Sciences. Dr. O’Neill received his Ph.D. in pharmacology from the University of London, carried out post-doctoral research at Cambridge U.K., and was elected a Fellow of the Royal Society in 2016.
Founded in 2014, Nuritas is solving the unmet medical needs of the world with the unparalleled capability to develop preventative and curative peptide-based treatments for disease with industry leading speed and accuracy. It is successfully doing so currently in collaboration with a number of industry leading multinationals. The company is changing the landscape of drug discovery by identifying novel peptides using a proprietary artificial intelligence (AI) platform, with in silico predictions validated by their in-house multidisciplinary team of scientists and laboratory. Nuritas engages in collaborative partnerships in the pharmaceutical and consumer goods industries to conduct peptide discovery that is faster, more accurate, and less expensive than traditional drug discovery.
Nuritas has received global recognition for the impact of its innovative technology which includes winning the overall Innovation Award at the Forbes Reinventing America Summit in 2015, the Nutrition Capital Network Venture competition in October 2016 and support from EU Horizon 2020 in 2016 for a peptide that carries the potential to prevent pre-diabetic patients from developing diabetes.
Allison Blum, Ph.D.
LifeSci Public Relations
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Følg saker fra GlobeNewswire
Registrer deg med din epostadresse under for å få de nyeste sakene fra GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra GlobeNewswire
Constellation Brands CEO Bill Newlands Signs CEO Action for Diversity & Inclusion Pledge20.6.2019 15:00:00 CEST | Pressemelding
VICTOR, N.Y., June 20, 2019 (GLOBE NEWSWIRE) -- Constellation Brands, Inc. (NYSE: STZ and STZ.B), a leading beverage alcohol company, announced today that that Bill Newlands, president and chief executive officer, is joining CEO Action for Diversity & Inclusion™ - the largest CEO-driven business commitment to advance diversity and inclusion within the workplace. The CEO Action for Diversity & Inclusion recognizes that change often happens when there’s support at the executive level. More than 600 CEOs of the world’s leading companies and business organizations are leveraging their voices to advance diversity and inclusion in the workplace by placing individual accountability on all—leaders and employees—to create inclusive environments. “At Constellation, we work hard to foster an inclusive culture that is characterized by diversity in background and thought, and that reflects our consumers and the communities where we live and work,” said Newlands. “Signing the CEO Action for Diversit
Radient Technologies Inc. Provides Update on Progress of Cannabis and Hemp Extraction Facilities and Issues Shares for Services20.6.2019 13:30:00 CEST | Pressemelding
EDMONTON, Alberta, June 20, 2019 (GLOBE NEWSWIRE) -- Radient Technologies Inc. (“Radient” or the “Company”) (TSX Venture: RTI; OTCQX: RDDTF) is pleased to announce it has awarded the mandate for the second phase of the construction of its Edmonton III manufacturing facility to Fillmore Construction Management Inc. (“Fillmore”). Construction is well underway, with footings and foundation work having been completed, and the structural component of the building now in progress and on schedule. Fillmore was selected by Radient due to its extensive previous experience developing food processing and GMP approved manufacturing plants. Edmonton III is Radient’s expanded capacity cannabis and hemp processing line that is expected to have a total annual throughput capacity of 280,000 kg/year of cannabis, and 2,800,000 kg/year of hemp upon completion in calendar 2020. Radient completed its first commercial extraction run for Aurora Cannabis Inc. (“Aurora”) (TSX: ACB; NYSE: ACB) in May 2019 at its
TeraRecon Receives First-of-Kind FDA Determination20.6.2019 11:00:00 CEST | Pressemelding
DURHAM, N.C., June 20, 2019 (GLOBE NEWSWIRE) -- Advanced visualization and artificial intelligence (AI) technology provider, TeraRecon, today announced it has successfully completed an FDA regulatory review of its Northstar™ AI Results Explorer, for which the technology and the determination are both firsts-of-kind in the medical imaging industry. Northstar is designed to work alongside the company’s EnvoyAI™ interoperability platform which includes FDA-cleared 3rd party content listed on its EnvoyAI Exchange marketplace. The Northstar determination letter reinforces the company’s commitment to regulatory and quality standards along with transparency in the field of medical imaging artificial intelligence. The Northstar AI Results Explorer provides an engaging physician user experience which can be integrated into the clinical systems already used throughout the health enterprise. Now with full commercial availability, Northstar can provide physicians an important way to accept, reject
Appian Named A Leader in Digital Process Automation for Deep Deployments Report by Independent Research Firm19.6.2019 16:28:00 CEST | Pressemelding
RESTON, Va, June 19, 2019 (GLOBE NEWSWIRE) -- Appian (NASDAQ: APPN) today announced it has been named a leader in “The Forrester Wave™: Software For Digital Process Automation For Deep Deployments, Q2 2019” report (“DPA Deep”). In Forrester’s four market segments for rapid application development, DPA Deep platforms “excel at the high end of process complexity but may also be the right solution to meet the needs for a wide-deployment, low-code standard” in an organization. In Forrester’s evaluation, Appian tied for the top score in the Current Offering category (including criteria for user experience development tools; process and flow design; digital decisioning, and robotic process automation). Appian also received among the second-highest scores in the Strategy category (including criteria like vision and strategy, commercial model, partners and training, community, and marketplace). The report notes that “Appian is a low-code vendor that thrives in complex process environments.” Th
Seaborn Networks announces new IP & Ethernet Services for Brazil and U.S. market19.6.2019 14:30:00 CEST | Pressemelding
BOSTON, June 19, 2019 (GLOBE NEWSWIRE) -- Seaborn Networks (“Seaborn”), a leading developer-owner-operator of subsea fiber optic cable systems, today announced that it will be delivering industry leading performance with new IP Service offerings comprising of diverse Ethernet Service and IP Service solutions addressing the market’s demand for rapidly deployed and highly stable global Ethernet & IP based needs between North and South America. IP Service offerings will include IP Transit, Remote Peering, Cloud Connect and Enterprise DIA solutions. Seaborn’s IP Services are offered under a minimal commitment with the ability to utilize additional bandwidth on a pay-as-you-use basis. Seaborn’s Ethernet Service offerings include E-Line, E-LAN and E-Tree capabilities with options for protected service depending on the Class of Service (CoS) selected. Industry leading SLA’s are provided on all IP and Ethernet services. “In today’s fast paced, highly complex communications environment, busines
Standard Lithium Announces Positive Preliminary Economic Assessment and Upgrading of Mineral Resource at Its Southern Arkansas Lithium Brine Project19.6.2019 09:00:00 CEST | Pressemelding
VANCOUVER, British Columbia, June 19, 2019 (GLOBE NEWSWIRE) -- Standard Lithium Ltd. (“Standard Lithium” or the “Company”) (TSXV: SLL) (OTCQX: STLHF) (FRA: S5L), is pleased to announce the results of a Preliminary Economic Assessment (PEA) of its 150,000 acre project in the south-central region of Arkansas, USA (the “Property”). The PEA considers the production of battery-quality lithium carbonate through a phased build-out to a total 20,900 tonnes per annum (tpa) from the contemplated joint venture with Lanxess Corp. (see press release dated November 12, 2018) at their three-operating bromine-processing plants. The PEA also includes the reclassification of the existing mineral resource to an Indicated category. The PEA was prepared by Advisian, the consulting arm of WorleyParsons Canada Services Ltd (Worley), a world-leading integrated engineering firm with extensive experience in the design and construction of chemical plants and lithium brine processing projects around the globe. Ke